Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New imaging agent RAD301 tested in small Early-Stage study

NCT ID NCT05799274

First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 25 times

Summary

This early-phase study is testing a new substance called RAD301 in 9 healthy volunteers and people with certain cancers (pancreatic, lung, esophageal, cervical, endometrial, or ovarian). The main goal is to see how RAD301 moves through the body and how much radiation reaches organs and tumors, as well as to check for side effects. Participants receive a single dose of RAD301 and are monitored closely. This study does not aim to treat cancer, but to gather important safety and imaging information.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Montefiore Medical Center

    RECRUITING

    The Bronx, New York, 10461, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • United Theranostics

    RECRUITING

    Princeton, New Jersey, 08540, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.